Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Empagliflozin versus NPH insulin for newly onset glucocorticoid-induced diabetes
2018-002640-82Phase 4Terminated
- Sponsor
- Nordsjællands Hospital
- Start
- Sep 2018
- Modality
- Small Molecules, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of empagliflozin and regular human insulin in steroid-induced diabetes (2 arms), sponsored by Nordsjællands Hospital. Started Sep 2018; status: terminated.
02
Drugs
empagliflozinregular human insulin
03
Conditions
steroid-induced diabetes
Beyond the preview
Go deeper on 2018-002640-82.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2018-002640-82.